2,208 Shares in Jazz Pharmaceuticals PLC $JAZZ Acquired by State of Wyoming

State of Wyoming bought a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 2,208 shares of the specialty pharmaceutical company’s stock, valued at approximately $417,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Cardinal Capital Management raised its stake in shares of Jazz Pharmaceuticals by 0.5% during the fourth quarter. Cardinal Capital Management now owns 14,538 shares of the specialty pharmaceutical company’s stock valued at $2,471,000 after acquiring an additional 66 shares during the last quarter. Bessemer Group Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 0.3% during the first quarter. Bessemer Group Inc. now owns 22,362 shares of the specialty pharmaceutical company’s stock worth $4,228,000 after purchasing an additional 73 shares during the period. UMB Bank n.a. grew its stake in shares of Jazz Pharmaceuticals by 12.6% in the fourth quarter. UMB Bank n.a. now owns 725 shares of the specialty pharmaceutical company’s stock worth $123,000 after purchasing an additional 81 shares during the last quarter. Pinnacle Associates Ltd. grew its stake in shares of Jazz Pharmaceuticals by 0.7% in the fourth quarter. Pinnacle Associates Ltd. now owns 11,203 shares of the specialty pharmaceutical company’s stock worth $1,905,000 after purchasing an additional 83 shares during the last quarter. Finally, Fifth Third Wealth Advisors LLC increased its holdings in Jazz Pharmaceuticals by 4.4% in the first quarter. Fifth Third Wealth Advisors LLC now owns 1,996 shares of the specialty pharmaceutical company’s stock valued at $377,000 after purchasing an additional 85 shares during the period. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. TD Cowen raised their target price on Jazz Pharmaceuticals from $220.00 to $275.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Deutsche Bank Aktiengesellschaft upped their price target on Jazz Pharmaceuticals from $250.00 to $270.00 and gave the company a “buy” rating in a research report on Thursday, July 9th. Sanford C. Bernstein restated a “market perform” rating on shares of Jazz Pharmaceuticals in a research report on Tuesday, June 9th. Truist Financial cut their price objective on Jazz Pharmaceuticals from $256.00 to $254.00 and set a “buy” rating on the stock in a research note on Tuesday, July 7th. Finally, Bank of America upped their target price on Jazz Pharmaceuticals from $281.00 to $307.00 and gave the company a “buy” rating in a report on Wednesday, June 10th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $259.06.

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock opened at $253.87 on Monday. Jazz Pharmaceuticals PLC has a twelve month low of $105.00 and a twelve month high of $256.75. The firm has a 50 day moving average price of $237.37 and a 200-day moving average price of $203.44. The company has a market capitalization of $15.95 billion, a P/E ratio of -12,687.16, a P/E/G ratio of 0.22 and a beta of 0.32. The company has a quick ratio of 1.85, a current ratio of 2.04 and a debt-to-equity ratio of 0.95.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 EPS for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. The company had revenue of $1.07 billion for the quarter. As a group, equities analysts predict that Jazz Pharmaceuticals PLC will post 21.9 EPS for the current year.

Insider Transactions at Jazz Pharmaceuticals

In related news, Director Rick E. Winningham sold 2,741 shares of the business’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $241.57, for a total value of $662,143.37. Following the sale, the director directly owned 9,567 shares in the company, valued at approximately $2,311,100.19. The trade was a 22.27% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Neena M. Patil sold 1,200 shares of the company’s stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $231.83, for a total transaction of $278,196.00. Following the sale, the executive vice president directly owned 51,549 shares in the company, valued at approximately $11,950,604.67. This trade represents a 2.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 13,098 shares of company stock valued at $3,131,906. 4.10% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.